E-viri
Recenzirano
Odprti dostop
-
Huespe, Ivan A.; Ferraris, Augusto; Lalueza, Antonio; Valdez, Pascual R.; Peroni, Maria L.; Cayetti, Luis A.; Mirofsky, Matias A.; Boietti, Bruno; Gómez‐Huelgas, Ricardo; Casas‐Rojo, José M.; Antón‐Santos, Juan M.; Núñez‐Cortés, Jesús M.; Lumbreras, Carlos; Ramos‐Rincón, Jose‐Manuel; Barrio, Noelia G.; Pedrera‐Jiménez, Miguel; Martin‐Escalante, María D.; Ruiz, Francisco R.; Onieva‐García, María Á.; Toso, Carlos R.; Risk, Marcelo R.; Klén, Riku; Pollán, Javier A.; Gómez‐Varela, David
Journal of medical virology, 20/May , Letnik: 95, Številka: 5Journal Article
The aim of this study was to analyze whether the coronavirus disease 2019 (COVID‐19) vaccine reduces mortality in patients with moderate or severe COVID‐19 disease requiring oxygen therapy. A retrospective cohort study, with data from 148 hospitals in both Spain (111 hospitals) and Argentina (37 hospitals), was conducted. We evaluated hospitalized patients for COVID‐19 older than 18 years with oxygen requirements. Vaccine protection against death was assessed through a multivariable logistic regression and propensity score matching. We also performed a subgroup analysis according to vaccine type. The adjusted model was used to determine the population attributable risk. Between January 2020 and May 2022, we evaluated 21,479 COVID‐19 hospitalized patients with oxygen requirements. Of these, 338 (1.5%) patients received a single dose of the COVID‐19 vaccine and 379 (1.8%) were fully vaccinated. In vaccinated patients, mortality was 20.9% (95% confidence interval CI: 17.9–24), compared to 19.5% (95% CI: 19–20) in unvaccinated patients, resulting in a crude odds ratio (OR) of 1.07 (95% CI: 0.89–1.29; p = 0.41). However, after considering the multiple comorbidities in the vaccinated group, the adjusted OR was 0.73 (95% CI: 0.56–0.95; p = 0.02) with a population attributable risk reduction of 4.3% (95% CI: 1–5). The higher risk reduction for mortality was with messenger RNA (mRNA) BNT162b2 (Pfizer) (OR 0.37; 95% CI: 0.23–0.59; p < 0.01), ChAdOx1 nCoV‐19 (AstraZeneca) (OR 0.42; 95% CI: 0.20–0.86; p = 0.02), and mRNA‐1273 (Moderna) (OR 0.68; 95% CI: 0.41–1.12; p = 0.13), and lower with Gam‐COVID‐Vac (Sputnik) (OR 0.93; 95% CI: 0.6–1.45; p = 0.76). COVID‐19 vaccines significantly reduce the probability of death in patients suffering from a moderate or severe disease (oxygen therapy).
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.